Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma.

Eric Van Cutsem,Margaret A. Tempero,Darren Sigal,Do-Youn Oh,Nicola Fazio,Teresa Macarulla,Erika Hitre,Pascal Hammel,Andrew Eugene Hendifar,Susan E. Bates,Chung-Pin Li,Sunil R. Hingorani,Christelle De La Fouchardiere,Anup Kasi,Volker Heinemann,Anthony Maraveyas,Nathan Bahary,Laura Layos,Vaibhav Sahai,Lei Zheng,Jill Lacy,Joon Oh Park,Fabienne Portales,Paul E. Oberstein,W. Wu,Dimitrios Chondros,Andrea J. Bullock,Halo Investigators

Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma.

2020

PURPOSETo evaluate the efficacy and safety of pegvorhyaluronidase alfa (PEGPH20) plus nab-paclitaxel/gemcitabine (AG) in patients with hyaluronan-high metastatic pancreatic ductal adenocarcinoma (P...

Keywords:

in patient
pancreatic ductal adenocarcinoma
Gemcitabine
Pathology
Nab-paclitaxel
Internal medicine
Metastatic Pancreatic Adenocarcinoma
Medicine
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations